BR112016006232A2 - derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inibidores de nik - Google Patents

derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inibidores de nik

Info

Publication number
BR112016006232A2
BR112016006232A2 BR112016006232A BR112016006232A BR112016006232A2 BR 112016006232 A2 BR112016006232 A2 BR 112016006232A2 BR 112016006232 A BR112016006232 A BR 112016006232A BR 112016006232 A BR112016006232 A BR 112016006232A BR 112016006232 A2 BR112016006232 A2 BR 112016006232A2
Authority
BR
Brazil
Prior art keywords
disorders
pyrrolo
pyrazol
compounds
pyridine derivatives
Prior art date
Application number
BR112016006232A
Other languages
English (en)
Other versions
BR112016006232B1 (pt
Inventor
Macleod Calum
Edward Clark David
Jean Ghislain ROUSSEL Fabien
Hynd George
Jozef Kulagowski Janusz
Gary Montana John
Tisselli Patrizia
Edward Mann Samuel
Colin Price Stephen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112016006232A2 publication Critical patent/BR112016006232A2/pt
Publication of BR112016006232B1 publication Critical patent/BR112016006232B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)

Abstract

a presente invenção refere-se a agentes farmacêuticos úteis para terapia e/ou profilaxia em um mamífero, e em particular a inibidores de quinase indutora de nf-¿b (nik - também conhecida como map3k14) úteis para o tratamento de doenças tais como câncer, distúrbios inflamatórios, distúrbios metabólicos e distúrbios autoimunes. a invenção está também dirigida a composições farmacêuticas compreendendo tais compostos, a processos para preparar tais compostos e composições, e ao uso de tais compostos ou composições farmacêuticas para a prevenção ou o tratamento de doenças tais como câncer, distúrbios inflamatórios, distúrbios metabólicos incluindo obesidade e diabetes, e distúrbios autoimunes.
BR112016006232-9A 2013-09-26 2014-09-25 Derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inibidores de nik e composição farmacêutica que os compreende BR112016006232B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13186148 2013-09-26
EP13186148.6 2013-09-26
EP14176125.4 2014-07-08
EP14176125 2014-07-08
PCT/EP2014/070489 WO2015044269A1 (en) 2013-09-26 2014-09-25 NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS

Publications (2)

Publication Number Publication Date
BR112016006232A2 true BR112016006232A2 (pt) 2017-08-01
BR112016006232B1 BR112016006232B1 (pt) 2022-11-29

Family

ID=51626028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006232-9A BR112016006232B1 (pt) 2013-09-26 2014-09-25 Derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inibidores de nik e composição farmacêutica que os compreende

Country Status (14)

Country Link
US (1) US9981963B2 (pt)
EP (1) EP3049412B1 (pt)
JP (1) JP6404332B2 (pt)
KR (1) KR102317335B1 (pt)
CN (1) CN105579452B (pt)
AU (1) AU2014327235B2 (pt)
BR (1) BR112016006232B1 (pt)
CA (1) CA2922633C (pt)
EA (1) EA028101B1 (pt)
ES (1) ES2643070T3 (pt)
IL (1) IL244702B (pt)
MX (1) MX365739B (pt)
TW (1) TWI627173B (pt)
WO (1) WO2015044269A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) * 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
MX371151B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
CN107074818B (zh) * 2014-10-23 2020-04-17 詹森药业有限公司 作为nik抑制剂的吡唑衍生物
ES2715104T3 (es) 2014-10-23 2019-05-31 Janssen Pharmaceutica Nv Nuevos derivados de pirazolopirimidina como inhibidores de nik
WO2016062792A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New compounds as nik inhibitors
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP3383390A4 (en) * 2015-12-02 2019-11-20 Astraea Therapeutics, LLC PIPERIDINYL COMPOUNDS FOR NOCICEPTIN RECEPTOR
BR112018014675B1 (pt) 2016-01-22 2023-12-19 Janssen Pharmaceutica Nv Derivados de cianoindolina substituída como inibidores de nik e composição farmacêutica que os compreende
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
AU2017289317B2 (en) * 2016-06-30 2021-04-01 Janssen Pharmaceutica Nv Cyanoindoline derivatives as NIK inhibitors
JPWO2020162638A1 (ja) * 2019-02-08 2021-12-16 学校法人近畿大学 悪性腫瘍改善用組成物
CN114222737B (zh) 2019-05-31 2024-07-26 詹森药业有限公司 NF-κB诱导激酶的小分子抑制剂
CN110156766A (zh) * 2019-06-04 2019-08-23 南京工业大学 一种银催化的氘代五元芳香杂环化合物的制备方法
WO2022138735A1 (ja) 2020-12-22 2022-06-30 学校法人近畿大学 悪性腫瘍疾患の改善用医薬組成物
TW202402269A (zh) * 2022-05-26 2024-01-16 大陸商迪哲（江蘇）醫藥股份有限公司 ＲＯＣＫ（Ｒｈｏ相關激酶）抑制劑及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
CA2564356A1 (en) 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
TW200736260A (en) * 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
CA2728767A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
EP2320895A2 (en) 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CN103476768B (zh) * 2011-03-16 2015-07-08 弗·哈夫曼-拉罗切有限公司 6,5-杂环炔丙醇化合物及其用途
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) * 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
WO2016062792A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New compounds as nik inhibitors
MX371151B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
CN107074818B (zh) 2014-10-23 2020-04-17 詹森药业有限公司 作为nik抑制剂的吡唑衍生物
ES2715104T3 (es) 2014-10-23 2019-05-31 Janssen Pharmaceutica Nv Nuevos derivados de pirazolopirimidina como inhibidores de nik

Also Published As

Publication number Publication date
EA201690657A1 (ru) 2016-08-31
KR20160060054A (ko) 2016-05-27
IL244702A0 (en) 2016-04-21
JP6404332B2 (ja) 2018-10-10
KR102317335B1 (ko) 2021-10-26
CA2922633A1 (en) 2015-04-02
ES2643070T3 (es) 2017-11-21
BR112016006232B1 (pt) 2022-11-29
EA028101B1 (ru) 2017-10-31
CN105579452A (zh) 2016-05-11
EP3049412B1 (en) 2017-07-12
WO2015044269A1 (en) 2015-04-02
CA2922633C (en) 2022-07-26
IL244702B (en) 2019-07-31
TWI627173B (zh) 2018-06-21
CN105579452B (zh) 2018-01-23
US20160229851A1 (en) 2016-08-11
AU2014327235B2 (en) 2018-02-08
AU2014327235A1 (en) 2016-03-17
MX2016003863A (es) 2016-08-04
JP2016531858A (ja) 2016-10-13
MX365739B (es) 2019-06-12
EP3049412A1 (en) 2016-08-03
US9981963B2 (en) 2018-05-29
TW201602103A (zh) 2016-01-16

Similar Documents

Publication Publication Date Title
BR112016006232A2 (pt) derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inibidores de nik
BR112016005914A2 (pt) derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inibidores de nik
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
BR112017007715A2 (pt) derivados de tienopirimidina como inibidores de nik
BR112017008039A2 (pt) derivados de pirazol como inibidores de nik
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
BR112017007704A2 (pt) derivados de pirazolopirimidina como inibidores de nik
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
BR112017008045A2 (pt) compostos como inibidores de nik
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
BR112018002547A2 (pt) benzimidazóis substituídos, sua preparação e seu uso como produtos farmacêuticos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2014, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.